Cargando…

In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma

Rationale: Intrinsic brain tumors, such as gliomas are largely resistant to immunotherapies including immune checkpoint blockade. Adoptive cell therapies (ACT) including chimeric antigen receptor (CAR) or T cell receptor (TCR)-transgenic T cell therapy targeting glioma-associated antigens are an eme...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunger, Jessica, Schregel, Katharina, Boztepe, Berin, Agardy, Dennis Alexander, Turco, Verena, Karimian-Jazi, Kianush, Weidenfeld, Ina, Streibel, Yannik, Fischer, Manuel, Sturm, Volker, Santarella-Mellwig, Rachel, Kilian, Michael, Jähne, Kristine, Sahm, Katharina, Wick, Wolfgang, Bunse, Lukas, Heiland, Sabine, Bunse, Theresa, Bendszus, Martin, Platten, Michael, Breckwoldt, Michael O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614679/
https://www.ncbi.nlm.nih.gov/pubmed/37908732
http://dx.doi.org/10.7150/thno.87248
_version_ 1785129072811048960
author Hunger, Jessica
Schregel, Katharina
Boztepe, Berin
Agardy, Dennis Alexander
Turco, Verena
Karimian-Jazi, Kianush
Weidenfeld, Ina
Streibel, Yannik
Fischer, Manuel
Sturm, Volker
Santarella-Mellwig, Rachel
Kilian, Michael
Jähne, Kristine
Sahm, Katharina
Wick, Wolfgang
Bunse, Lukas
Heiland, Sabine
Bunse, Theresa
Bendszus, Martin
Platten, Michael
Breckwoldt, Michael O.
author_facet Hunger, Jessica
Schregel, Katharina
Boztepe, Berin
Agardy, Dennis Alexander
Turco, Verena
Karimian-Jazi, Kianush
Weidenfeld, Ina
Streibel, Yannik
Fischer, Manuel
Sturm, Volker
Santarella-Mellwig, Rachel
Kilian, Michael
Jähne, Kristine
Sahm, Katharina
Wick, Wolfgang
Bunse, Lukas
Heiland, Sabine
Bunse, Theresa
Bendszus, Martin
Platten, Michael
Breckwoldt, Michael O.
author_sort Hunger, Jessica
collection PubMed
description Rationale: Intrinsic brain tumors, such as gliomas are largely resistant to immunotherapies including immune checkpoint blockade. Adoptive cell therapies (ACT) including chimeric antigen receptor (CAR) or T cell receptor (TCR)-transgenic T cell therapy targeting glioma-associated antigens are an emerging field in glioma immunotherapy. However, imaging techniques for non-invasive monitoring of adoptively transferred T cells homing to the glioma microenvironment are currently lacking. Methods: Ultrasmall iron oxide nanoparticles (NP) can be visualized non-invasively by magnetic resonance imaging (MRI) and dedicated MRI sequences such as T(2)* mapping. Here, we develop a protocol for efficient ex vivo labeling of murine and human TCR-transgenic and CAR T cells with iron oxide NPs. We assess labeling efficiency and T cell functionality by flow cytometry and transmission electron microscopy (TEM). NP labeled T cells are visualized by MRI at 9.4 T in vivo after adoptive T cell transfer and correlated with 3D models of cleared brains obtained by light sheet microscopy (LSM). Results: NP are incorporated into T cells in subcellular cytoplasmic vesicles with high labeling efficiency without interfering with T cell viability, proliferation and effector function as assessed by cytokine secretion and antigen-specific killing assays in vitro. We further demonstrate that adoptively transferred T cells can be longitudinally monitored intratumorally by high field MRI at 9.4 Tesla in a murine glioma model with high sensitivity. We find that T cell influx and homogenous spatial distribution of T cells within the TME as assessed by T(2)* imaging predicts tumor response to ACT whereas incomplete T cell coverage results in treatment resistance. Conclusion: This study showcases a rational for monitoring adoptive T cell therapies non-invasively by iron oxide NP in gliomas to track intratumoral T cell influx and ultimately predict treatment outcome.
format Online
Article
Text
id pubmed-10614679
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-106146792023-10-31 In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma Hunger, Jessica Schregel, Katharina Boztepe, Berin Agardy, Dennis Alexander Turco, Verena Karimian-Jazi, Kianush Weidenfeld, Ina Streibel, Yannik Fischer, Manuel Sturm, Volker Santarella-Mellwig, Rachel Kilian, Michael Jähne, Kristine Sahm, Katharina Wick, Wolfgang Bunse, Lukas Heiland, Sabine Bunse, Theresa Bendszus, Martin Platten, Michael Breckwoldt, Michael O. Theranostics Research Paper Rationale: Intrinsic brain tumors, such as gliomas are largely resistant to immunotherapies including immune checkpoint blockade. Adoptive cell therapies (ACT) including chimeric antigen receptor (CAR) or T cell receptor (TCR)-transgenic T cell therapy targeting glioma-associated antigens are an emerging field in glioma immunotherapy. However, imaging techniques for non-invasive monitoring of adoptively transferred T cells homing to the glioma microenvironment are currently lacking. Methods: Ultrasmall iron oxide nanoparticles (NP) can be visualized non-invasively by magnetic resonance imaging (MRI) and dedicated MRI sequences such as T(2)* mapping. Here, we develop a protocol for efficient ex vivo labeling of murine and human TCR-transgenic and CAR T cells with iron oxide NPs. We assess labeling efficiency and T cell functionality by flow cytometry and transmission electron microscopy (TEM). NP labeled T cells are visualized by MRI at 9.4 T in vivo after adoptive T cell transfer and correlated with 3D models of cleared brains obtained by light sheet microscopy (LSM). Results: NP are incorporated into T cells in subcellular cytoplasmic vesicles with high labeling efficiency without interfering with T cell viability, proliferation and effector function as assessed by cytokine secretion and antigen-specific killing assays in vitro. We further demonstrate that adoptively transferred T cells can be longitudinally monitored intratumorally by high field MRI at 9.4 Tesla in a murine glioma model with high sensitivity. We find that T cell influx and homogenous spatial distribution of T cells within the TME as assessed by T(2)* imaging predicts tumor response to ACT whereas incomplete T cell coverage results in treatment resistance. Conclusion: This study showcases a rational for monitoring adoptive T cell therapies non-invasively by iron oxide NP in gliomas to track intratumoral T cell influx and ultimately predict treatment outcome. Ivyspring International Publisher 2023-09-25 /pmc/articles/PMC10614679/ /pubmed/37908732 http://dx.doi.org/10.7150/thno.87248 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Hunger, Jessica
Schregel, Katharina
Boztepe, Berin
Agardy, Dennis Alexander
Turco, Verena
Karimian-Jazi, Kianush
Weidenfeld, Ina
Streibel, Yannik
Fischer, Manuel
Sturm, Volker
Santarella-Mellwig, Rachel
Kilian, Michael
Jähne, Kristine
Sahm, Katharina
Wick, Wolfgang
Bunse, Lukas
Heiland, Sabine
Bunse, Theresa
Bendszus, Martin
Platten, Michael
Breckwoldt, Michael O.
In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
title In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
title_full In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
title_fullStr In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
title_full_unstemmed In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
title_short In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
title_sort in vivo nanoparticle-based t cell imaging can predict therapy response towards adoptive t cell therapy in experimental glioma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614679/
https://www.ncbi.nlm.nih.gov/pubmed/37908732
http://dx.doi.org/10.7150/thno.87248
work_keys_str_mv AT hungerjessica invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT schregelkatharina invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT boztepeberin invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT agardydennisalexander invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT turcoverena invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT karimianjazikianush invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT weidenfeldina invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT streibelyannik invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT fischermanuel invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT sturmvolker invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT santarellamellwigrachel invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT kilianmichael invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT jahnekristine invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT sahmkatharina invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT wickwolfgang invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT bunselukas invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT heilandsabine invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT bunsetheresa invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT bendszusmartin invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT plattenmichael invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma
AT breckwoldtmichaelo invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma